The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care

BACKGROUND: The EMPA‐REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with cardiovascular disease. EMPRISE is a study programme on the effectiveness, safety and healthcare utilization of empagliflozi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Endocrinol Diabetes Metab
Main Authors: Patorno, Elisabetta, Najafzadeh, Mehdi, Pawar, Ajinkya, Franklin, Jessica M., Déruaz‐Luyet, Anouk, Brodovicz, Kimberly G., Santiago Ortiz, Adrian J., Bessette, Lily G., Kulldorff, Martin, Schneeweiss, Sebastian
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6947693/
https://ncbi.nlm.nih.gov/pubmed/31922030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/edm2.103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados